Grace Mellgren, MD
Ophthalmology · Roswell, NMNPI 1184709339
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,137 of the $1,590 with a category attached, or 71.5%. 15 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 39.6% of the total. Reporting peaked in 2019 at $781 and has fallen 70.8% since, to $228 in 2025.
Across 47 payments — averaging $33.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$630
- Johnson & Johnson Surgical Vision, Inc.$269
- Bausch & Lomb Americas Inc.$173
- Rayner Intraocular Lenses Limited$87
- Ivantis, Inc$74
- Sight Sciences, Inc.$69
- plus $289 from 9 others
What the payments were for
- Travel & lodging$41726%
- Food & beverage$1,13772%
- Gifts$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 8 | $630 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $269 |
| Bausch & Lomb Americas Inc. | 6 | $173 |
| Rayner Intraocular Lenses Limited | 5 | $87 |
| Ivantis, Inc | 3 | $74 |
| Sight Sciences, Inc. | 4 | $69 |
| Glaukos Corporation | 3 | $55 |
| Alcon | 1 | $45 |
| Carl Zeiss Meditec USA, Inc. | 1 | $36 |
| AbbVie | 2 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $31 |
| Amgen | 2 | $31 |
| Rxsight Inc | 1 | $23 |
| Astellas Pharma US Inc | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$521
How this compares
$1,590 in reported general payments places this provider in the 55th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Travoprost | 51 | $10,072 |
| LumiganBimatoprost | 17 | $8,909 |
| Restasis MultidoseCyclosporine | 14 | $8,697 |
| Brinzolamide | 11 | $7,085 |
| Latanoprost | 407 | $5,876 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $4,910 |
| Brimonidine Tartrate | 144 | $2,379 |
| Timolol Maleate | 152 | $2,012 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 106 | $1,707 |
| Prednisolone Acetate | 23 | $1,418 |
| Dorzolamide Hcl | 69 | $1,142 |
| Pilocarpine Hcl | 20 | $1,076 |
| Ketorolac Tromethamine | 35 | $764 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis Multidose | $34 | $17,60731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 81 ophthalmology providers in New Mexico.
Other ophthalmology in Roswell
- Paul EngstromRoswell$669
- Mark GallardoLas Cruces$1.2M
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Paul GulbasRuidoso$14K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
- Ian ThompsonAlbuquerque$10K
- Paul SanchezAlbuquerque$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.